Bullish & Foolish
Full ELOX fundamentals All 466 on the Survival Watch

ELOXELOXX PHARMACEUTICALS, INC.

Is Eloxx Pharmaceuticals struggling financially?

Yes, by its own account. Eloxx Pharmaceuticals told the SEC on 5 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

  • Share sales and shelf filings

    Further, assuming we become current in our filing obligations, we will not be eligible to register the offer and sale of our securities using a shelf registration statement on Form S-3 until we have timely filed all periodic reports required under the Exchange Act for one year.

    Form 10-K, filed 17 Mar 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$84.7M
Source filing
10-Q 5 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash and short-term investments

$62.0M

What Eloxx Pharmaceuticals told the SEC

…incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability. Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern. If we fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents, the value of our intellectual property rights would diminish,…

ELOXX PHARMACEUTICALS, INC., Form 10-Q, filed 5 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 14427.0% share-count increase The company issued stock. Each share now owns 99.3% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt